JGC
NAMS icon

J. Goldman & Co’s NewAmsterdam Pharma NAMS Stock Holding History

J. Goldman & Co’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-36,776
Closed -$706K – 565
2024
Q2 		$706K Sell
36,776
-42,058
-53% -$844K 0.02% 333
2024
Q1 		$1.86M Buy
+78,834
New +$1.6M 0.06% 227

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

J. Goldman & Co's NAMS Position: Q3 2024 in Review

J. Goldman & Co sold out of NewAmsterdam Pharma (NAMS) in Q3 2024, closing a stake of 36,776 shares — an estimated $706K sold.

J. Goldman & Co first reported a position in NAMS in Q1 2024 and held it in 2 quarters. The position peaked at $1.86M in Q1 2024. 100 funds tracked by Wall St. Rank hold NAMS as of Q3 2024.

  • J. Goldman & Co reported no remaining NewAmsterdam Pharma position as of Q3 2024 after selling out during the quarter.
  • J. Goldman & Co sold 36,776 NewAmsterdam Pharma shares in Q3 2024, an estimated $706K.
  • J. Goldman & Co first reported a position in NewAmsterdam Pharma in Q1 2024 and held it in 2 quarters.
  • J. Goldman & Co's NewAmsterdam Pharma position peaked at $1.86M in Q1 2024.
  • 100 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q3 2024.

Based on J. Goldman & Co's 13F filing for Q3 2024, filed 14 Nov 2024.